Table 3. BCLC stage and cancer burden in training and validation groups subdivided for the result of the combined-sequential AFP test (AFP-BC/Δ6+ AFP).
|
Training group |
Validation group |
|||||
|---|---|---|---|---|---|---|
| Variable | AFP-BC/Δ6+ AFP negative (n=16) | AFP-BC/Δ6+ AFP positive (n=64) | P | AFP-BC/Δ6+ AFP negative (n=7) | AFP-BC/Δ6+ AFP positive (n=29) | P |
| Number of lesions | 0.772 | 0.813 | ||||
| Monofocal | 12 (75) | 47 (73.5) | 5 (71.4) | 22 (75.9) | ||
| Paucifocal | 4 (25) | 15 (23.4) | 2 (28.6) | 6 (20.7) | ||
| Multifocal | 0 (0) | 2 (3.1) | 0 (0) | 1 (3.4) | ||
| Size of the largest lesion (mm) | 2.1 (1–3.3) | 2.3 (0.8–4.8) | 0.201 | 2.7 (1.2–4.5) | 2.1 (1–5.3) | 0.841 |
| BCLC | 0.391 | 0.618 | ||||
| Very-early | 5 (31.2) | 13 (20.3) | 3 (42.9) | 9 (31.1) | ||
| Early | 11 (68.8) | 38 (59.4) | 4 (57.1) | 17 (58.6) | ||
| Intermediate | 0 (0) | 9 (14.1) | 0 (0) | 3 (10.3) | ||
| Advanced | 0 (0) | 2 (3.1) | 0 (0) | 0 (0) | ||
| End-stage | 0 (0) | 2 (3.1) | 0 (0) | 0 (0) | ||
Values are expressed as number (%) or median with range.
AFP-BC=alpha-fetoprotein best-cut-off at the time of HCC detection; Δ6+ AFP=increasing alpha-fetoprotein in the semester prior to HCC detection; BCLC=Barcelona Clinic Liver Cancer.